700874-71-1 | LY2109761

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$19.00	$14.00
2mg	98%	in stock	$23.00	$17.00
5mg	98%	in stock	$32.00	$22.00
10mg	98%	in stock	$48.00	$34.00
25mg	98%	in stock	$96.00	$68.00
50mg	98%	in stock	$163.00	$114.00
250mg	98%	in stock	$436.00	$306.00

Description

• Catalog Number: AH14588
• Chemical Name: LY2109761
• CAS Number: 700874-71-1
• Molecular Formula: C26H27N5O2
• Molecular Weight: 441.52487999999994
• MDL Number: MFCD12923354
• SMILES: O1CCN(CC1)CCOc1ccc2c(c1)nccc2c1c2CCCn2nc1c1ccccn1

Computed Properties

• Complexity: 632
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 6
• XLogP3: 2.8

Literature

• In vitro and ex vivo anti-fibrotic effects of LY2109761, a small molecule inhibitor against TGF-β.

  Toxicology and applied pharmacology 20180915

• Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.

  BMC cancer 20150101

• Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.

  Toxicology 20141204

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

• Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

  Bone 20120301

• Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

  Neoplasia (New York, N.Y.) 20110601

• Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.

  Cancer research 20110315

• Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

  Molecular cancer 20100101

• Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.

  Hepatology (Baltimore, Md.) 20091001

• Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.

  Hepatology (Baltimore, Md.) 20090301

• Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

  Journal of medicinal chemistry 20080410

• LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.

  Molecular cancer therapeutics 20080401